全文获取类型
收费全文 | 15834篇 |
免费 | 846篇 |
国内免费 | 71篇 |
专业分类
耳鼻咽喉 | 148篇 |
儿科学 | 334篇 |
妇产科学 | 475篇 |
基础医学 | 1879篇 |
口腔科学 | 522篇 |
临床医学 | 1266篇 |
内科学 | 4479篇 |
皮肤病学 | 438篇 |
神经病学 | 1387篇 |
特种医学 | 327篇 |
外科学 | 2347篇 |
综合类 | 97篇 |
一般理论 | 2篇 |
预防医学 | 1157篇 |
眼科学 | 231篇 |
药学 | 826篇 |
中国医学 | 69篇 |
肿瘤学 | 767篇 |
出版年
2024年 | 10篇 |
2023年 | 159篇 |
2022年 | 378篇 |
2021年 | 647篇 |
2020年 | 348篇 |
2019年 | 538篇 |
2018年 | 713篇 |
2017年 | 416篇 |
2016年 | 421篇 |
2015年 | 483篇 |
2014年 | 713篇 |
2013年 | 848篇 |
2012年 | 1317篇 |
2011年 | 1337篇 |
2010年 | 677篇 |
2009年 | 619篇 |
2008年 | 1038篇 |
2007年 | 964篇 |
2006年 | 914篇 |
2005年 | 899篇 |
2004年 | 796篇 |
2003年 | 636篇 |
2002年 | 643篇 |
2001年 | 109篇 |
2000年 | 120篇 |
1999年 | 109篇 |
1998年 | 105篇 |
1997年 | 71篇 |
1996年 | 77篇 |
1995年 | 62篇 |
1994年 | 53篇 |
1993年 | 37篇 |
1992年 | 46篇 |
1991年 | 31篇 |
1990年 | 33篇 |
1989年 | 30篇 |
1988年 | 27篇 |
1987年 | 23篇 |
1986年 | 34篇 |
1985年 | 20篇 |
1984年 | 24篇 |
1983年 | 18篇 |
1982年 | 23篇 |
1981年 | 22篇 |
1980年 | 22篇 |
1979年 | 10篇 |
1978年 | 12篇 |
1974年 | 14篇 |
1973年 | 21篇 |
1972年 | 14篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
Brenes Monge Alexander Fernández Elorriaga María Poblano Verástegui Ofelia Valdez Santiago Rosario Martínez Nolasco Manuel A. Yáñez Álvarez Iraís Saturno Hernández Pedro J. 《Maternal and child health journal》2021,25(4):565-573
Maternal and Child Health Journal - To identify and describe the frequency and characteristics of disrespect and abuse practices towards women during facility-based delivery in four hospitals in... 相似文献
72.
Carlos R Ferreira Kristina Kintzinger Mary E Hackbarth Ulrike Botschen Yvonne Nitschke M Zulf Mughal Genevieve Baujat Dirk Schnabel Eric Yuen William A Gahl Rachel I Gafni Qing Liu Pedro Huertas Gus Khursigara Frank Rutsch 《Journal of bone and mineral research》2021,36(11):2193-2202
Generalized arterial calcification of infancy (GACI) is a rare disorder caused by ENPP1 or ABCC6 variants. GACI is characterized by low pyrophosphate, arterial calcification, and high mortality during the first year of life, but the natural course and possible differences between the causative genes remain unknown. In all, 247 individual records for patients with GACI (from birth to 58.3 years of age) across 19 countries were reviewed. Overall mortality was 54.7% (13.4% in utero or stillborn), with a 50.4% probability of death before the age of 6 months (critical period). Contrary to previous publications, we found that bisphosphonate treatment had no survival benefit based on a start-time matched analysis and inconclusive results when initiated within 2 weeks of birth. Despite a similar prevalence of GACI phenotypes between ENPP1 and ABCC6 deficiencies, including arterial calcification (77.2% and 89.5%, respectively), organ calcification (65.8% and 84.2%, respectively), and cardiovascular complications (58.4% and 78.9%, respectively), mortality was higher for ENPP1 versus ABCC6 variants (40.5% versus 10.5%, respectively; p = 0.0157). Higher prevalence of rickets was reported in 70.8% of surviving affected individuals with ENPP1 compared with that of ABCC6 (11.8%; p = 0.0001). Eleven affected individuals presenting with rickets and without a GACI diagnosis, termed autosomal recessive hypophosphatemic rickets type 2 (ARHR2), all had confirmed ENPP1 variants. Approximately 70% of these patients demonstrated evidence of ectopic calcification or complications similar to those seen in individuals with GACI, which shows that ARHR2 is not a distinct condition from GACI but represents part of the spectrum of ENPP1 deficiency. Overall, this study identified an early mortality risk in GACI patients despite attempts to treat with bisphosphonates, high prevalence of rickets almost exclusive to ENPP1 deficiency, and a spectrum of heterogenous calcification and multiple organ complications with both ENPP1 and ABCC6 variants, which suggests an overlapping pathology. © 2021 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR). This article has been contributed to by US Government employees and their work is in the public domain in the USA. 相似文献
73.
74.
Gustavo Martinez-Mier Pedro I. Moreno-Ley Luis F. Budar-Fernández Marco T. Méndez-López Carlos A. Allende-Castellanos Luis A. Jiménez-López Daniel A. Barrera-Amoros Edgar Aguilar-Sandoval Maritza De la Paz-Román Ernesto Soto-Miranda Yamilli Rivera-Sanchez Mónica Martínez-Maldonado 《Transplantation proceedings》2021,53(3):1005-1009
ContextThymoglobulin is used effectively as induction agent in kidney transplantation but the optimal dose is not well established.ObjectiveDemonstrate that low-dose thymoglobulin (3 mg/kg) has similar efficacy and safety compared to basiliximab induction in low-risk kidney transplantation under standard maintenance immunosuppressionDesign, Setting, ParticipantsProspective randomized study in kidney transplant patients (12/2016-05/2018). Inclusion criteria: Recipients > 18 years, first living donor transplant. Exclusion criteria: Second and multiorgan transplant, ABO incompatibility, positive cross-match, panel reactive antibodies (PRA) > 30%, positive donor-specific antibody, human immunodeficiency virus, hepatitis B surface antigen, hepatitis C virus positive, white blood cells < 2000 cells/mm3, platelets < 75,000 cells/mm3 and malignancy.InterventionGroup A: basiliximab (20 mg D0 and D4). Group B: thymoglobulin (3 mg/kg total). Maintenance immunosuppression: tacrolimus, mycophenolate mofetil, and steroids.Main Outcome MeasuresBiopsy-proven acute rejection (BPAR), delayed graft function, slow graft function, leukopenia, infections, adverse events, graft loss, estimated glomerular filtration rate, and death within 12 months.Results100 patients (basiliximab, n = 53) (thymoglobulin, n = 47) were included. Donor and recipient characteristics were similar except for longer dialysis (basiliximab), PRA class I (1.2% basiliximab, 4.5% thymoglobulin), HLA match (basiliximab 2.8, thymoglobulin 2.2), and cytomegalovirus status. BPAR rate was basiliximab 3.8% and thymoglobulin 6.4% (P = ns). Delayed graft function (basiliximab 3.8%; thymoglobulin 4.3%), slow graft function, and 12-month leukopenia (basiliximab 11.3%, thymoglobulin 21.3%) were similar between groups (P = ns). There was no difference in infections and adverse events between groups. Patient and graft survival were as follows: basiliximab 98.1% and 92.5%, thymoglobulin 100% and 93.6% (P = ns).ConclusionLow-dose thymoglobulin induction (3 mg/kg) can be used effectively and safely in low-risk kidney transplantation with good results during the first year post-transplant. 相似文献
75.
76.
77.
Jessica L. H. Phillips Mitchell K. Freedman Jeremy I. Simon Pedro K. Beredjiklian 《Hand (New York, N.Y.)》2021,16(2):164
Background: The Patient-Reported Outcomes Measurement Information System Upper Extremity (PROMIS UE) computer adaptive test was developed to improve precision and reduce question burden. We hypothesized that in patients with carpal tunnel syndrome (CTS): (1) PROMIS UE would correlate with established patient-reported outcome measures (PROs); (2) the time and number of questions required would be lower than current metrics; (3) there would be no floor or ceiling effects; and (4) PROMIS UE would not correlate with disease severity. Methods: Patients undergoing electrodiagnostic evaluation found to have a primary diagnosis of unilateral CTS prospectively completed PROMIS UE, Quick Disabilities of the Arm, Shoulder and Hand (qDASH), and Boston Carpal Tunnel Syndrome Questionnaire (BCTQ). Electrophysiologic and clinical severity was recorded. The relationships among PROs were described with Spearman coefficients. A floor or ceiling effect was confirmed if >15% of patients achieved the lowest or highest possible score, respectively. Results: Fifty-one patients (average, 53.9 years) were enrolled. An excellent correlation was identified between PROMIS UE and qDASH (R = −0.76, P < .001). There was a good correlation between PROMIS UE and BCTQ (R = −0.58, P < 0.001). The PROMIS UE required less time and fewer questions than qDASH and BCTQ (P = .02 and P < .001). There were no floor or ceiling effects. Neither neurophysiologic nor clinical severity correlated with PROMIS UE (R = 0.24, P > .05 and R = −0.18, P > .05). Conclusions: The PROMIS UE has an excellent correlation with qDASH and a good correlation with BCTQ in patients with CTS. Furthermore, PROMIS UE required less time and fewer questions than established PROs. Used as a single PRO, PROMIS UE represents a practical alternative to current metrics in patients with CTS. 相似文献
78.
Daniel López-Padilla Francisco García-Río Adolfo Alonso-Arroyo Nuria Arenas Valls Alicia Cerezo Lajas Marta Corral Blanco Virginia Gallo González Milagros Llanos Flores María Martínez Redondo Natalia Martos Gisbert Elena Ojeda Castillejo Marta Padilla Bernáldez Marta Pérez Gallán Vania Prudencio Ribera Luis Puente Maestu Beatriz Recio Moreno Elena Rodríguez Jimeno Ana Sánchez Azofra José Ignacio de Granda-Orive 《Archivos de bronconeumologia》2021,57(2):146-147
79.
Alice Rosi Pedro Mena Fabio Castello Daniele Del Rio 《International journal of food sciences and nutrition》2021,72(1):70-81
AbstractInformation on children’s diet including bioactive compounds is quite scarce. This observational study investigated the composition of the diet of children living in Parma (Italy; n?=?172, 8–10?years) using 3-day food records completed in winter and spring. Mean daily intakes of food groups, energy and nutrients were obtained using the national food database, while (poly)phenol contents were estimated from Phenol-Explorer or by specific literature searches. Food consumption, energy and nutrient intakes decreased in spring and were partially in line with national data. Adherence to the nutritional recommendations was not satisfied for the majority of nutrients. Main contributors to the phenolic intake were flavonoids (flavan-3-ols) and phenolic acids (hydroxycinnamic acids), while main dietary sources were fruit, chocolate-based products, vegetables, and tea & coffee (decaffeinated). This study provided the first comprehensive analysis of the nutritional composition of children’s diet. Future research should look at the health implications of dietary choices in children. 相似文献
80.
Salcedo M Taja L Utrera D Chávez P Hidalgo A Pérez C Benítez L Castañeda C Delgado R Gariglio P 《International journal of experimental pathology》2002,83(6):275-286
The role of tumour suppressor genes in the development of human cancers has been studied extensively. In viral carcinogenesis, the inactivation of suppressor proteins such as retinoblastoma (pRb) and p53, and cellular oncogenes overexpression, such as c-myc, has been the subject of a number of investigations. In uterine-cervix carcinomas, where high-risk human papillomavirus (HPV) plays an important role, pRb and p53 are inactivated by E7 and E6 viral oncoproteins, respectively. However, little is known about the in situ expression of some of these proteins in pre-malignant and malignant cervical tissues. On the other hand, it has also been demonstrated that c-myc is involved in cervical carcinogenesis, and that pRb participates in the control of c-myc gene expression. By using immunostaining techniques, we investigated pRb immunodetection pattern in normal tissues, squamous intraepithelial lesions (SILs) and invasive carcinomas from the uterine cervix. Our data show low pRb detection in both normal cervical tissue and invasive lesions, but a higher expression in SILs. C-Myc protein was observed in most of the cellular nuclei of the invasive lesions, while in SILs was low. These findings indicate a heterogeneous pRb immunostaining during the different stages of cervical carcinogenesis, and suggest that this staining pattern could be a common feature implicated in the pathogenesis of uterine-cervix carcinoma. 相似文献